Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran

Acta Tropica

Volumn 103, Issue 1, 2007, Pages 33-40

  Mohebali, M ^a   Fotouhi, A ^a   Hooshmand, B ^b   Zarei, Z ^a   Akhoundi, B ^a   Rahnema, A ^c   Razaghian, A R ^c   Kabir, M J ^c   Nadim, A ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MINISTRY OF HEALTH AND MEDICAL EDUCATION   (Iran)

^c Provincial Health Center   (Iran)

Author keywords

Cutaneous leishmaniasis; Iran; Leishmania major; Meglumine antimoniate; Miltefosine; Treatment

Indexed keywords

MEGLUMINE ANTIMONATE; MILTEFOSINE;

ANTIMICROBIAL ACTIVITY; COMPARATIVE STUDY; DISEASE TREATMENT; DRUG; GASTROENTERITIS; HOSPITAL SECTOR; LEISHMANIASIS; LESION; SYMPTOM;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EPITHELIZATION; FEMALE; FEVER; HEADACHE; HUMAN; IRAN; LEISHMANIA MAJOR; MAJOR CLINICAL STUDY; MALE; NAUSEA; OPEN STUDY; PAIN; PATIENT COMPLIANCE; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN LEISHMANIASIS; THORAX PAIN; VOMITING;

ADOLESCENT; ADULT; ANIMALS; ANTIPROTOZOAL AGENTS; FEMALE; HUMANS; IRAN; LEISHMANIASIS, CUTANEOUS; MALE; MEGLUMINE; ORGANOMETALLIC COMPOUNDS; PHOSPHORYLCHOLINE; ZOONOSES;

ASIA; EURASIA; IRAN; MIDDLE EAST;

LEISHMANIA MAJOR;

EID: 34447558375     PISSN: 0001706X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.actatropica.2007.05.005     Document Type: Article

References (28)

1. Asilian A., Sadeghinia S., Faghihi G., and Momeni A.Z. Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate vs. cryotherapy and interalesional meglumine antimoniate alone for the treatment of cutaneous leishmaniasis. Int. J. Dermatol. 43 (2004) 281-283
2. Berman J. Miltefosine to treatment leishmaniasis: drug evaluation. Expert Opin. Pharmacother. 6 8 (2005) 1381-1388
3. Chico M.E., Guderian R.H., Cooper P.J., Armijos R., and Grogi M. Evaluation of a direct immunofluorescent antibody (DIFMA) test using Leishmania genus - specific monoclonal antibody in the routine diagnosis of cutaneous leishmaniasis. Rev. Soc. Dras. Med. Trop. 28 (1995) 99-103
4. Diseases Management Center, Ministry of Health, Treatment and Medical Education of Iran; 2002-2003. Annual Communicable Diseases Report.
5. Edrissian Gh.H., Nadim A., Alborzi A.V., and Ardehali S. Visceral leishmaniasis: the Iranian experiences. Arch. Iranian Med. J. 1 (1999) 22-26
6. Hadighi R., Mohebali M., Boucher P., Hajjaran H., Khamesipour A., and Ouellette M. Unresponsiveness to Glucantime treatment in Iranian Cutaneous leishmaniasis due to drug resistant Leishmania tropica parasites. PLOS. Med. 3 5 (2006) e 162 Epub 2006 Apr 18
7. Jha T.K., Sundar S., Thakur C.P., Bachmann P., Karbwang J., Fischer C., Voss A., and Berman J. Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N. Engl. J. Med. 341 (1999) 1795-1800
8. Kuhlencord A., Maniera T., Eibl H., and Unger C. Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice. Antimicrob. Agents Chemother. 36 (1992) 1630-1634
9. Lira R., Contreras L.M., Rta R.M., and Urbina J.A. Mechanism of action of anti-proliferative lysophospholipid analogues against protozoan parasite Trypanosoma cruzi: potentiation of in vitro activity by the sterol biosynthesis inhibitor Ketoconazole. J. Antimicrob. Chemother. 47 (2001) 237-546
10. Mohebali M., Hamzavi Y., Edrissian Gh.H., and Frouzani A. Seroepidemiological study of visceral leishmaniasis among humans and animal reservoirs in Bushehr province, Islamic Republic of Iran. East. Mediterr. Health J. 7 (2001) 912-917
11. Mohebali M., Motazedian M.H., Parsa F., and Hajjaran H. Identification of Leishmania species from different parts of Iran using a random amplified polymorphic DNA in human animal reservoirs and vectors. Med. J. Islamic Rep. Iran 15 (2002) 243-246
12. Mohebali M., Javadian E., Yaghoobi-Ershadi M.R., Akhavan A.A., Abaei M.R., and Hajjaran H. Study on Leishmania infection in caught rodents in some parts of I.R. of Iran. East. Mediterr. Health J. 10 (2004) 591-599
13. Mohebali M., Hajjaran H., Hamzavi Y., Mobedi I., Arshi Sh., Zarei Z., Akhoundi B., Manouchehri-Naieni K., Avizeh R., and Fakhar M. Epidemiological aspects of canine visceral leishmaniosis in the Islamic Republic of Iran. Vet. Parasitol. 129 (2005) 243-251
14. Momeni A.Z., and Aminjavaheri M. Treatment of non-healing cases of cutaneous leishmaniasis. Successful treatment using a combination of meglumine antimoniate plus allopurinol. E.J.D. 13 (2003) 40-43
15. Nadim A., and Seyedi-Rashti M.A. A brief review of the epidemiology of various types of leishmaniasis in Iran. Acta Med. Iranica XIV (1971) 99-106
16. Sindermann H., and Engel J. Development of miltefosine as an oral treatment for leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 100S (2006) S17-S20
17. Soto J., Toledo J., Gutierrez P., Nicholls R.S., Padilla J., Engel J., Fischer C., Voss A., and Berman J. Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin. Infect. Dis. 33 (2001) e57-e61
18. Soto J., Arana B., and Toledo J. Miltefosine for new world cutaneous leishmaniasis. Clin. Infect. Dis. 38 9 (2004) 1266-1272
19. Soto J., Valda-Rodriquez L., Toledo J., Vera-Navarro L., Luz M., Monasterios-Torrico H., Vega J., and Berman J. Comparison of generic to branded pentavalent antimony for treatment of new world cutaneous leishmaniasis. Am. J. Trop. Med. Hyg. 71 (2004) 577-581
20. Soto J., and Soto P. Miltefosine: oral treatment of leishmaniasis. Expert Rev. Anti Infect. Ther. 4 (2006) 177-185
21. Sundar S., Rosenkaimer F., Makharia M.K., Goyal A.K., Mandal A.K., Voss A., Hilgard P., and Murray H.W. Trial of oral miltefosine for visceral leishmaniasis. Lancet 352 (1998) 1821-1823
22. Sundar S., Gupta L.B., Makharia M.K., Singh M.K., Voss A., Rosenkaimer F., Engel J., and Murray H.W. Oral treatment of visceral leishmaniasis with miltefosine. Ann. Trop. Med. Parasitol. 93 (1999) 589-597
23. Sundar S., Makharia A., More D.K., Agraval G., Voss A., Fischer C., Bachmann P., and Murray H.W. Short course of oral miltefosine for treatment of visceral leishmaniasis. Clin. Infect. Dis. 31 (2000) 1110-1113
24. Sundar S., Jha T., Thakur C., Engel J., Sindermann H., and Fischer C. Miltefosine for Indian visceral leishmaniasis. N. Engl. J. Med. 347 (2002) 1739-1746
25. Vanlerberghe V., Diap G., Guerin P.J., Meheus F., Gerstl S., Van der Stuyft P., and Boelaert M. Drug policy for visceral leishmaniasis: Cost-effectiveness analysis. Trop. Med. Int. Health 12 (2007) 274-283
26. Yaghoobi-Ershadi M.R., Hanafi-Bojd A.A., Akhavan A.A., Zahraei-Ramazani A.R., and Mohebali M. Epidemiological study in a new focus of cutaneous leishmaniasis due to Leishmania major in Ardestan town, central Iran. Acta Trop. 79 (2001) 115-121
27. Yaghoobi M.R., Hanafi A.A., Javadian E., Jafari R., and Mohebali M. A new focus of cutaneous leishmaniasis caused by Leishmania tropica. Saudi Med. J. 24 (2002) 98-101
28. Zuffery R., and Mamoun C.B. Choline transport in Leishmania major promastigotes and its inhibition by choline and phosphocholine analogs. Mol. Biochem. Parasitol. 125 (2005) 127-134